Evidence map›Paper›PMID 32987195›Full record

ArticleCellular immunology2020

CD4

Richard Y Fu, Alex C Chen, Meghan J Lyle, Chun-Yu Chen, Chao Lien Liu, Carol H Miao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. 3-in-oneiScience · 2025
    Article
  5. The curious case of AAV immunology.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Role of FoxP3Human gene therapy · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Multipurposing CARs: Same engine, different vehicles.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Richard Y FuCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Alex C ChenCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Meghan J LyleCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Chun-Yu ChenCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Chao Lien LiuCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA.
Carol H MiaoCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. Electronic address: Carol.Miao@seattlechildrens.org.
University of Washington · US

Funding

Defining the role of altered cytokine signaling pathways on autoimmunityU01AI101990 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2016
$12.1M
Temple Project 1: Genetic characterization of factor VIII Inhibitors and glydosylation patternsU54HL142019 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI LI, LEI, MIAO, CAROL H · 2018 to 2022
$6.9M
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapyR01HL134321 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2016 to 2026
$6.2M
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia AR01HL151077 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2020 to 2023
$3.2M
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia AR01HL123326 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2016 to 2019
$1.9M
NHLBI NIH HHS R01 HL123326NHLBI NIH HHS R01 HL134321NHLBI NIH HHS R01 HL151077NHLBI NIH HHS U54 HL142019NIAID NIH HHS U01 AI101990
6 · The paper itself

Abstract

Although protein replacement therapy provides effective treatment for hemophilia A patients, about a third of severe patients develop neutralizing inhibitor antibodies to factor VIII. Adoptive transfer of regulatory T cells (Tregs) has shown promise in treating unwanted immune responses. In previous studies, transferred polyclonal Tregs ameliorated the anti-factor VIII immune responses in hemophilia A mice. In addition, factor VIII-primed Tregs demonstrated increased suppressive function. However, antigen-specific Tregs are a small fraction of the total lymphocyte population. To generate large numbers of factor VIII-specific Tregs, the more abundant murine primary CD4

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingCD4-Positive T-LymphocytesFactor VIIIForkhead Transcription FactorsGenetic TherapyHEK293 CellsHemophilia AHumansImmune ToleranceImmunotherapy, AdoptiveMaleMiceMice, Inbred C57BLReceptors, Chimeric AntigenAntibodies, MonoclonalAntibodies, NeutralizingFactor VIIIForkhead Transcription FactorsFoxp3 protein, mouseReceptors, Chimeric AntigenAdoptive cell therapyAntibody responseAnti-factor VIII inhibitorsCAR-TregsChimeric antigen receptorFactor VIIIHemophilia ARegulatory T cellsTolerance induction

Identifiers

PMID32987195
PMCPMC7655680
OpenAlexW3087143787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.